Mounjaro in Michigan (2026)
tirzepatide · GLP-1 weight management · Michigan
About Mounjaro
FDA-approved tirzepatide for type 2 diabetes. Off-label for weight loss is common.
See the full Mounjaro review for dosing, efficacy data, side effects, and the full pharmacy + telehealth program comparison.
Insurance coverage for Mounjaro in Michigan
Since January 1, 2026, Michigan Medicaid covers GLP-1s for obesity only for morbid obesity, after documented failure of other weight-loss interventions including PDL-preferred anti-obesity drugs, and only to avoid bariatric surgery. Prior authorizations approved before the change stay valid until their 6-month term ends.
| Carrier | Mounjaro status | Detail |
|---|---|---|
| Aetna | Covered | Mounjaro is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public Aetna coverage document for Mounjaro, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card. |
| Blue Cross Blue Shield | Covered (prior auth required) | Blue Cross Blue Shield of Massachusetts continues to cover Mounjaro for type 2 diabetes with prior authorization that includes a documented diabetes diagnosis, after ending weight-loss GLP-1 coverage in 2026. Other Blue plans set their own rules. |
| UnitedHealthcare | Covered | Mounjaro is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public UnitedHealthcare coverage document for Mounjaro, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card. |
| Cigna | Covered | Mounjaro is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public Cigna coverage document for Mounjaro, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card. |
| Humana | Covered | Medicare Part D, including Humana drug plans, covers Mounjaro for type 2 diabetes. Check Humana's formulary for your plan's tier and prior authorization rules. |
| Kaiser Permanente | Covered | Mounjaro is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public Kaiser Permanente coverage document for Mounjaro, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card. |
| Anthem | Covered | Mounjaro is FDA-approved for type 2 diabetes, not for weight loss. We have not found a public Anthem commercial coverage document for Mounjaro, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card. |
| Medicare | Covered | Part D plans cover Mounjaro for type 2 diabetes; tier and prior authorization depend on your plan's formulary. People with type 2 diabetes get GLP-1s through their Part D plan and cannot use the Medicare GLP-1 Bridge. |
| Medicaid | Covered | MassHealth lists Mounjaro as a preferred GIP/GLP-1 drug for diabetes, and California Medi-Cal keeps Mounjaro on its drug list restricted to type 2 diabetes. Neither covers it for weight loss. |
| TRICARE | Covered (prior auth required) | TRICARE covers Mounjaro for type 2 diabetes for all beneficiaries with prior authorization, plus a medical necessity form for the formulary copayment and for coverage at a military pharmacy. |
Telehealth and prescribing in Michigan
A telehealth clinician must be licensed in Michigan to prescribe Mounjaro to you while you are in Michigan.
Michigan's IMLC membership lapsed on March 28, 2025 and was restored by Public Act 6 of 2026 (HB 5455), signed March 26, 2026.
- Source: Michigan Legislature: HB 5455
Platforms differ in which drugs they prescribe, insurance handling, and clinical model. See our platform comparisons.
Compounded tirzepatide
On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.
Mounjaro in Michigan: common questions
Is Mounjaro legal in Michigan?+
Yes. Mounjaro (tirzepatide) is FDA-approved and legal in all 50 US states including Michigan. State-level differences appear in Medicaid coverage and clinician licensing, not in the legality of the medication itself.
Can I get Mounjaro via telehealth in Michigan?+
Yes, from a clinician licensed in Michigan. A telehealth clinician must be licensed in Michigan to prescribe Mounjaro to you while you are in Michigan. Michigan's IMLC membership lapsed on March 28, 2025 and was restored by Public Act 6 of 2026 (HB 5455), signed March 26, 2026.
Does Michigan Medicaid cover Mounjaro?+
Limited coverage for weight loss. Since January 1, 2026, Michigan Medicaid covers GLP-1s for obesity only for morbid obesity, after documented failure of other weight-loss interventions including PDL-preferred anti-obesity drugs, and only to avoid bariatric surgery. Prior authorizations approved before the change stay valid until their 6-month term ends.
What's the cheapest way to get Mounjaro in Michigan?+
The main paths are insurance with prior authorization if your plan covers it, manufacturer cash-pay programs, or telehealth programs that include the medication. NovoCare Pharmacy sells Wegovy pens to cash-pay patients for $349 a month ($199 a month for the first two months for new patients through December 31, 2026). LillyDirect sells Zepbound vials for $299 (2.5 mg), $399 (5 mg), and $449 (7.5 to 15 mg) a month when refilled on time.
Is compounded Mounjaro still available in Michigan?+
Compounding rules are federal, not set by Michigan. On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.